For Q1 FY2026 ended March 31, 2026, IRadimed reported revenue of $21.98 million, up 12.6% year-over-year. Net income was $5.82 million, a 24.1% increase, and operating income rose 33.2% to $7.24 million. Diluted EPS grew 21.6% to $0.45. The company had $56.37 million in cash and $98.51 million in equity, with no long-term debt.
•Revenue increased 12.6% YoY to $21.98 million.
•Net income rose 24.1% YoY to $5.82 million.
•Operating income grew 33.2% YoY to $7.24 million.
•Diluted EPS was $0.45, up 21.6% from the prior year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
IRADIMED develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets.
Its portfolio also includes 3880 MRI compatible patient vital signs monitoring system, and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.
The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and globally. Incorporated in 1992, the company is headquartered in Orlando, Florida.
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. Its main products include the MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets, as well as the 3880 MRI compatible patient vital signs monitoring system. The company also offers the 3600 FMD1 ferromagnetic detection device with remote alarm logging unit, non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. These products are designed for use in MRI environments, ensuring patient safety and accurate drug delivery and monitoring.
Where is IRADIMED CORPORATION (IRMD) listed and in which currency?
IRADIMED CORPORATION is listed on the NasdaqGM exchange under the ticker symbol IRMD. The company's stock trades in United States Dollars (USD). As a U.S.-based company, its financial reporting and stock transactions are conducted in USD, which is the official currency of the United States. Investors can buy and sell shares of IRMD on the Nasdaq Global Market, which is a major U.S. stock exchange known for listing technology and growth-oriented companies.
What sector and industry does IRADIMED CORPORATION (IRMD) operate in?
IRADIMED CORPORATION operates in the Healthcare sector, specifically within the Medical Devices industry. This means the company is involved in designing, manufacturing, and selling medical equipment used by healthcare providers. In particular, IRADIMED focuses on devices that are compatible with magnetic resonance imaging (MRI) environments, such as infusion pump systems and patient vital signs monitors. The Medical Devices industry is highly regulated and requires rigorous testing and compliance with safety standards, which IRADIMED adheres to in order to provide reliable products for hospitals and imaging centers.
Where is IRADIMED CORPORATION (IRMD) headquartered and what markets does it serve?
IRADIMED CORPORATION is headquartered in Orlando, Florida, United States. The company was incorporated in 1992. It serves hospitals, acute care facilities, and outpatient imaging centers both in the United States and globally. IRADIMED sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. This multi-channel approach allows the company to reach a wide range of customers, from large hospital networks to specialized imaging centers, ensuring that its MRI-compatible medical devices are available to healthcare providers worldwide.
How does IRADIMED CORPORATION (IRMD) generate revenue?
IRADIMED CORPORATION generates revenue by selling its MRI-compatible medical devices and related accessories. The company's primary revenue streams come from the sale of its MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump Systems, along with the associated disposable IV tubing sets, which are consumables that generate recurring revenue. Additionally, IRADIMED sells the 3880 MRI compatible patient vital signs monitoring system, the 3600 FMD1 ferromagnetic detection device, non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring sensors and accessories. The company also provides clinical application specialists to support product implementation, which may be included in the product price or offered as a service. By targeting hospitals, acute care facilities, and outpatient imaging centers, IRADIMED addresses a niche market of MRI-compatible equipment, which is essential for patient safety during MRI procedures.